Sanofi's Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows
Sanofi reports positive phase 3 HERCULES study data for tolebrutinib in non-relapsing secondary progressive multiple sclerosis, showing a 31% delay in disability progression. Study also revealed increased disability improvement,
MedPage Today on MSN22h
Kids With MS May Have Better Outcomes When Started on High-Efficacy Treatment EarlyAmong 282 patients with pediatric-onset MS, 39% started high-efficacy therapy early (at ages 12-17), and 61% started late ...
Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...
PHILADELPHIA.Today on MSN14h
Local Multiple Sclerosis Advocate Honored With State CitationBucks County resident Joseph “Smiley” Terinoni was recently presented with a citation from the Pennsylvania House of ...
Medpage Today on MSN3d
Higher Comorbidity Burden in Multiple Sclerosis Tied to Worse Outcomes"Those with the highest burden of comorbidity had over a 30% increased risk of having disability worsening," Salter said. "In ...
A study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple ...
Vitamin D is linked to a 34% reduction in the relative risk for disease activity in patients with clinically isolated ...
Available disease-modifying therapies can prevent relapses and relapse-associated worsening in people with multiple sclerosis by targeting autoimmunity through various mechanisms. However, these ...
New research presented today at European Committee for Treatment and Research in Multiple Sclerosis 2024 reveals that ...
Patients with MS showed half the rate of amyloid pathology compared with people without MS, suggesting a possible protective ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback